Cargando…
Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers
PURPOSE: Midostaurin (PKC412), a multitargeted tyrosine kinase inhibitor that targets FMS-related tyrosine kinase 3 and KIT, is in clinical trials for the treatment for acute myeloid leukemia and advanced systemic mastocytosis. In vitro studies showed that midostaurin is predominantly metabolized by...
Autores principales: | Dutreix, Catherine, Munarini, Florence, Lorenzo, Sebastien, Roesel, Johannes, Wang, Yanfeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3834177/ https://www.ncbi.nlm.nih.gov/pubmed/24085261 http://dx.doi.org/10.1007/s00280-013-2287-6 |
Ejemplares similares
-
Comparison of two endogenous biomarkers of CYP3A4 activity in a drug–drug interaction study between midostaurin and rifampicin
por: Dutreix, Catherine, et al.
Publicado: (2014) -
Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers
por: del Corral, Adam, et al.
Publicado: (2012) -
Drug-Drug Interaction Analysis of Pyronaridine/Artesunate and Ritonavir in Healthy Volunteers
por: Morris, Carrie A., et al.
Publicado: (2012) -
Drug‐Drug Interaction Study of Apixaban with Cyclosporine and Tacrolimus in Healthy Volunteers
por: Bashir, Babar, et al.
Publicado: (2018) -
Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers
por: Lesko, Lawrence J., et al.
Publicado: (2017)